Stockreport

New England Journal of Medicine Publishes Results of Pivotal Phase 3 Reblozyl® (luspatercept-aamt) MEDALIST Trial

Acceleron Pharma Inc.  (XLRN) 
Last acceleron pharma inc. earnings: 2/27 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.acceleronpharma.com/investor-relations
PDF Data from MEDALIST showed significant clinical benefit of Reblozyl in treating anemia in adults with myelodysplastic syndromes PRINCETON, N.J. & CAMBRIDGE, Mass.--(BU [Read more]